Exploiting novel cell cycle targets in the development of anticancer agents

In this review we provide a brief background on the cell cycle and then focus on two novel and emerging areas of cell cycle research that may prove to have significant relevance to the development of novel anticancer agents. In particular, we review the emerging evidence to suggest that histone deac...

Full description

Saved in:
Bibliographic Details
Published inCurrent cancer drug targets Vol. 5; no. 2; p. 85
Main Authors Wong, Chung Fai, Guminski, Alexander, Saunders, Nicholas A, Burgess, Andrew J
Format Journal Article
LanguageEnglish
Published Netherlands 01.03.2005
Subjects
Animals
Antineoplastic Agents - administration & dosage
Cell Cycle - drug effects
Cell Cycle - physiology
Drug Delivery Systems - methods
Drug Delivery Systems - trends
Humans
Technology, Pharmaceutical - methods
Technology, Pharmaceutical - trends
Online AccessGet more information

Cover

More Information
Summary:In this review we provide a brief background on the cell cycle and then focus on two novel and emerging areas of cell cycle research that may prove to have significant relevance to the development of novel anticancer agents. In particular, we review the emerging evidence to suggest that histone deacetylase inhibitors may possess cancer cell-specific cytotoxicity due to their ability to target a novel G2/M checkpoint. We also review the recent literature supporting the proposition that inhibition of E2F activity in epithelial cancer cells may prove to be a useful differentiation therapy that operates via cell cycle-dependent and cell cycle-independent mechanisms.
ISSN:1568-0096
DOI:10.2174/1568009053202090